Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics
Journal of Clinical Medicine · 04.12.2023 · 12 (23) · 7486
DOI: 10.3390/jcm12237486 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 04.12.2023. Verfasst von Valentina Pala und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Clinic, Medical Sciences Department, University of Turin, 10121 Torino, Italy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Vitiligo, the most prevalent skin depigmenting disease, is characterized by the selective loss of melanocytes, impacting patients’ quality of life significantly. This autoimmune disorder progresses through a complex interplay of genetic and non-genetic factors, posing challenges in comprehending its pathogenesis and devising effective treatment strategies for achieving remission. Existing conventional therapeutic approaches, such as topical and oral corticosteroids, calcineurin inhibitors, and phototherapy, lack specificity, offer modest efficacy, and may entail potential adverse effects. Consequently, there is a pressing need for a more nuanced understanding of vitiligo’s pathogenesis to pave the way for targeted therapeutic innovations. This review aims to provide a comprehensive overview of recent developments and findings concerning Januse Kinase (JAK) inhibitors and biologics tested in vitiligo patients. JAK inhibitors have exhibited promising results, showcasing both efficacy and tolerability. In contrast, the outcomes of biologics treatment have been more varied. However, to establish a clearer understanding of which specific pathways to target for a more effective approach to vitiligo, additional in vitro studies and extensive clinical research involving a larger population are imperative.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dermatology Clinic, Medical Sciences Department, University of Turin, 10121 Torino, Italy.
ORCID-Profile: Simone Ribero, Luca Mastorino
Zitieren
APA
Pala, V., Ribero, S., Quaglino, P., & Mastorino, L. (2023). Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics. Journal of Clinical Medicine, 12(23), 7486. https://doi.org/10.3390/jcm12237486
Vancouver
Pala V, Ribero S, Quaglino P, Mastorino L. Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics. Journal of Clinical Medicine. 2023;12(23):7486. doi:10.3390/jcm12237486
BibTeX
@article{Pala2023,
author = {Pala, Valentina and Ribero, Simone and Quaglino, Pietro and Mastorino, Luca},
title = {Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {23},
pages = {7486},
doi = {10.3390/jcm12237486}
}
EUVIMED